NICE in the UK recommends Dapagliflozin (FORXIGA) to treat heart failure with reduced ejection fraction for patients with or without Diabetes.

European commission approves forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults. PRESS RELEASE Dapagliflozin is the first SGLT2 inhibitor approved in the European Union (EU) for adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D). Almost one […]